Announcements
Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance


In this issue


Home Eurosurveillance Edition  2015: Volume 20/ Issue 7 Article 5
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 7, 19 February 2015
Review articles
Assessment of human influenza pandemic scenarios in Europe
  1. Istituto Superiore di Sanità (ISS), Rome, Italy
  2. Basque Institute for Agricultural Research and Development, Biscay, Spain
  3. Retroscreen Virology, London, United Kingdom
  4. Open Rome, Paris, France
  5. Niddam European Community Lawyer, Budapest, Hungary
  6. Polish National Institute of Public Health, Warsaw, Poland
  7. Romanian National Institute of Public Health, Bucharest, Romania
  8. University of Crete, Crete, Greece
  9. World Health Organization (WHO), Geneva, Switzerland
  10. European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
  11. Ministry of Health, Elderly and Community Care, Valletta, Malta
  12. Université Claude Bernard Lyon 1, Lyon, France
  13. Université Paris Descartes, Paris, France

Citation style for this article: Napoli C, Fabiani M, Rizzo C, Barral M, Oxford J, Cohen JM, Niddam L, Goryński P, Pistol A, Lionis C, Briand S, Nicoll A, Penttinen P, Gauci C, Bounekkar A, Bonnevay S, Beresniak A. Assessment of human influenza pandemic scenarios in Europe. Euro Surveill. 2015;20(7):pii=21038. Article DOI: http://dx.doi.org/10.2807/1560-7917.ES2015.20.7.21038
Date of submission: 08 January 2014

The response to the emergence of the 2009 influenza A(H1N1) pandemic was the result of a decade of pandemic planning, largely centred on the threat of an avian influenza A(H5N1) pandemic. Based on a literature review, this study aims to define a set of new pandemic scenarios that could be used in case of a future influenza pandemic. A total of 338 documents were identified using a searching strategy based on seven combinations of keywords. Eighty-three of these documents provided useful information on the 13 virus-related and health-system-related parameters initially considered for describing scenarios. Among these, four parameters were finally selected  (clinical attack rate, case fatality rate, hospital admission rate, and intensive care admission rate) and four different levels of severity for each of them were set. The definition of six most likely scenarios results from the combination of four different levels of severity of the four final parameters (256 possible scenarios). Although it has some limitations, this approach allows for more flexible scenarios and hence it is far from the classic scenarios structure used for pandemic plans until 2009.


Introduction

Before the 2009 influenza A(H1N1) pandemic, most European Union (EU) Member States had developed preparedness plans in order to timely respond to an eventual pandemic. Many of these plans involve explicit or implicit planning assumptions on what can be expected during a pandemic and on how a pandemic virus might behave [1].

The response to the emergence of the 2009 influenza A(H1N1) pandemic was the result of a decade of pandemic planning, largely centred on the threat of an avian influenza A(H5N1) pandemic. However, the influenza A(H5N1) and the 2009 pandemic influenza A(H1N1) viruses have markedly different characteristics in terms of mortality among confirmed cases and human-to-human transmission [2,3]. Moreover, the 2009 pandemic influenza A(H1N1) virus caused illness that did not require hospitalisation in the vast majority of cases, and was a highly transmissible virus among humans spreading to several countries within days [3,4].

In this situation, the severity assessment applied during the 2009 influenza A(H1N1) pandemic using a variety of indicators leading to a qualitative assessment in three levels (i.e. mild, moderate and severe) was not specific enough to guide interventions [5,6].

After the pandemic, the International Health Regulations (IHR) Pandemic Review Committee encouraged the World Health Organization (WHO) to develop and utilise measures to assess the severity of every influenza epidemic by applying, evaluating and refining tools to measure severity every year [7]. WHO has recently developed a new document for Pandemic Influenza Risk Management [8].

The 2009 influenza pandemic highlighted the importance of quantitatively defining different scenarios; severity should be assessed as early as possible during a pandemic and continually re-assessed as the pandemic evolves and new information becomes available.

This work has been conducted in the frame of the European Commission project FLURESP (Cost-effectiveness assessment of European influenza human pandemic alert and response strategies) with the aim to define a set of scenarios to be used for a future pandemic planning (www.fluresp.eu).

Methods

Literature review and selection  of parameters
The literature search was conducted by consulting Medline, restricting it to articles published until December 2011. Seven different sets of keywords were considered (Table 1).

Table 1. Sets of keywords used in searching scientific articles and number of articles retrieved for the study on pandemic influenza scenarios in Europe


 
A systematic selection  procedure was conducted in two steps by two researchers independently. In the first step, the major topics of the articles were assessed by title and abstract. In this phase of the selection  procedure, all articles reporting epidemiological data on influenza pandemics were included. In case of doubt on the article’s relevant information, the article was included in the second selection  step.

In the second step, the full text articles, previously selected , were assessed. These articles were included in the review if they reported at least one of the following 13 parameters: basic reproductive number (R0); clinical attack rate (CAR); age-specific CAR; case fatality rate (CFR); communicability/generation interval; modes of transmission; incubation period; timing and duration of pandemic; clinical consultation rate (CCR); hospital admission rate (HAR); intensive care admission rate (ICAR); work absenteeism; bed occupancy rate (BOR). If the articles included did not contain information on at least one of the parameters listed above or if the study design was of low quality (e.g. small sample size, unclear definition of outcomes), they were excluded. Moreover, pertinent related citations were considered.

Of each article included in the review, the following data were recorded: year of the study, year of pandemic referring to, country, and described parameters.

International technical reports were obtained by consulting the websites of the European Centre for Disease Prevention and Control (ECDC) and WHO. Influenza pandemic preparedness plans for the European Union/European Economic Area (EU/EEA) countries were obtained from the ECDC website [9]. We also considered relevant studies based on mathematical modelling published in the literature but not retrieved through the search strategy.

Parameters collected through the literature review were subsequently discussed within the FURESP Project by a panel of experts composed of collaborators from international (WHO and ECDC) and national public health organisations (from France, Italy, Spain and the United Kingdom) who selected  the parameters to be used for defining scenarios.

Definition of severity profiles and scenarios
For each of the selected  parameters, four severity profiles were defined. In order to set the profiles, ranges of variability for each of the parameters were categorised into a four-group scale, according to a quartile distribution. We then adjusted the ranges for each of the four groups, according to the suggestions made by the panel of experts. Based on the possible combination of the four severity profiles of each of the four parameters, a set of scenarios were defined.

Results

Parameters selected
From the literature review we collected information on 13 parameters as potential candidates for defining the pandemic scenario. These parameters were divided into eight virus-related (R0; CAR; age-specific CAR; CFR; communicability/generation interval; modes of transmission; incubation period; timing and duration of pandemic) and five health-system-related (CCR; HAR; ICAR; work absenteeism; BOR).

The panel of experts was of the opinion that some of the parameters collected through the literature review were more relevant for mathematical modelling than for public health purposes, and others were considered less relevant for defining scenarios; consequently, all these were excluded: R0; age-specific CAR; communicability/generation interval; modes of transmission; incubation period; timing and duration of pandemic. For example, R0 (the average number of secondary infections produced by a single infected individual while they are infectious, in an entirely susceptible population), incubation period, and the generation interval (defined as the mean duration between time of infection of a secondary infected individual and the time of infection of their primary infector), are measures of the degree of transmissibility of an infection and in combination might affect CAR. Age-specific CAR in most of the considered influenza pandemics were derived from studies conducted in small and selected  communities not representative of the entire population, while the timing and duration of pandemic is expected to be from several weeks to a few months but will likely vary from country to country or within a single country. Therefore, these parameters were not considered in this study. Additionally, the contribution and clinical importance of potentially different modes of transmission of influenza are unknown and therefore were considered not relevant.

Thus, according to the opinion of the panel of experts, four parameters were selected  to be used for defining scenarios for pandemic planning. The two virus-related parameters are listed below with their limitations:

  • CAR, the proportion of the population with clinical symptoms over a specified period of time. Some individuals may not develop symptoms severe enough to be readily identified as acute respiratory infection (ARI) or influenza-like-illness (ILI). The measured CAR is thus not always the number of individuals who actually develop symptoms, and may also include the number of individuals seeking healthcare.
  • CFR, represented by the proportion of individuals who develop influenza symptoms, and die because of complications. The measured CFR could be affected by the laboratory confirmation that may be unavailable to validate the total number of cases. Moreover, the confirmation is likely biased to more severe cases. This results in an overestimation of the clinical severity of the disease, especially in case of people with underlying conditions that are at higher risk of death.

The health-system-related parameters deal with virulence (i.e. the ability of the virus to invade the tissues of the host and produce pathologic effects and complications) and impact (i.e. the effect on the healthcare sector) of the virus on the population. The most relevant health-system-resource utilisation parameters used to define pandemic scenarios are listed below with their limitations:

  • HAR, represented by the proportion of population hospitalised for confirmed influenza independently from the presence of complications. This measure is strongly affected by how the healthcare systems in different countries are structured.
  • ICAR, the proportion of hospitalisations for confirmed influenza that are treated in an intensive care unit (ICU) for influenza complications.

The ICAR could also be related to the level of virulence of the virus, since it is a proxy for the level of severity.

Literature review
A total of 338 documents (including technical reports and scientific articles and reviews) were identified using our search strategy with the seven sets of keywords. Of these, 17 were duplicated articles and 238 showed no relevant information on the selected  parameters (Figure 1). In conclusion, 83 articles and documents reporting information on the parameters listed above were considered for this study. 

Figure 1. Flowchart outlining the selection  of documents for the study on pandemic influenza scenarios in Europe


 
The year of publication of these documents ranges from 2003 to 2011 with more than half of the documents published between 2009 and 2010. When evaluating the performance of keywords’ combinations selected , 26% (83/321) of the detected documents provided useful information on the parameters for defining scenarios. The largest number of documents was detected using three sets of keywords (293/321, 91%) (Table 1).

The keywords combination ‘human influenza pandemic description’ provided the highest proportion of useful documents (10/28, 36%).

The range estimates for the parameters derived from the 83 selected  documents and their specific references are listed in Table 2.

Table 2. Range of values and references for the main parameters selected  for the study on pandemic influenza scenarios in Europe


 
Of the 83 relevant articles, 23 articles reported information on R0, with values ranging from 0.99 to 3.75. Thirty-four reported data on CAR, whose values ranged widely between 0 and 50%, while eight documents provided some information on age-specific CAR. For the CFR, 30 articles showed a range between 0 and 25%. Only three articles dealt with the generation interval, whose range was 1.6–4.1 days. The duration of infectiousness, reported in five articles, ranged between one and 21 days. Only seven articles provided generic descriptions of possible modes of transmission: all of them reported the respiratory route by droplets of infected secretions and/or hand-face contact after touching a contaminated person or surface. The incubation period, described in 12 articles, ranged from 0.5 to seven days, while the pandemic duration varied from 0 to 180 days according to seven articles. Moving to health system resource utilisation parameters, CCR ranged from 14% to 73% (seven articles); HAR ranged from 0% to 27.5% (26 articles); ICAR ranged from 0% to 34% (13 articles); work absenteeism ranged from 0 to 40% (seven articles); and BOR was between 0% and 37% of total critical care bed capacity according to one article.

Parameters collected from historical influenza pandemics
We also investigated parameters collected during the three significant influenza pandemics that occurred in the 20th century: 1918/19, 1957/58, and 1968/69 to 1969/70 (two waves) [5,10,11] (Table 3).

Table 3. Relevant parameters collected in the four past influenza pandemics for the study on pandemic influenza scenarios in Europe


 
In some European countries (UK in particular) there were three waves associated with the 1918/19 pandemic [12]. In the UK, the wave structure of this pandemic is not well understood; the final 1919 wave may have been a separate pandemic of a different virus to the 1918 waves. The smallest of the waves was in July–August 1918, the largest second wave was from October 1918 to January 1919, and the third wave was from February to April 1919 [13]. Estimates of the national CAR vary in the UK, but suggest that nationally it was around 25% of the population (totalled over all waves). The highest CAR were observed in the young population. Estimates of the CFR are around 2%, relatively evenly spread across the population, though with an excess in young adults [12]. The 1957/58 pandemic had one wave. Estimates of the CAR vary, but suggest that nationally it was around 30% of the population. Estimates of the CFR are around 0.1–0.2%. These average figures mask the considerable variation by age, most deaths being in the older adult population. However, the highest number of cases was registered in the young individuals [14]. The 1968/69 pandemic came in two waves in Europe [15]. Estimates of the national CAR vary, but based on comparisons with the epidemic in the United States (US), it may have been around 35% of the population [12]. Estimates of the CFR are less than 0.2%. These average figures for mortality mask the considerable variation by age, again, with most deaths recorded in the older adult population.

Parameters collected from the 2009 influenza pandemic
The recent influenza A(H1N1) pandemic in 2009/10 produced no major signal of excess deaths in the overall population [16], and most of the EU countries have reported data on those that have died from confirmed 2009 pandemic influenza A(H1N1) as a result of influenza A(H1N1) virus infection, but case ascertainment is unlikely to have been complete, and the true number is almost certainly higher [17-19].

Rates from the ILI surveillance systems across Europe showed that consultations were highest in the young. There was only one wave, except for the UK where two ‘waves’, one immediately following the other, were observed. There were high levels of background immunity among elderly.

In general, estimates of the CAR for the 2009 pandemic influenza A(H1N1) vary among countries: 0.01% in the central region of Portugal [20], 0.072% in Mexico [21], 18.3% in New Zealand [22], 30% in the Netherlands [23]. Across Europe the estimated CAR was 30% [24]. This variation reflects the different methods used to get the data: e.g. seroprevalence studies, epidemiological studies in different populations, mathematical models, etc. Other experiences in smaller groups of population provide additional results: 3.15% in a train in China [25], 4% in a primary school in China [26], 22% on a Peruvian Navy ship [27], 28.5% during an outbreak investigation in Nepal [28].

In the UK, figures used to track the epidemic suggest a CAR of 1–2% and modelling studies suggest that these estimates reflect only around 10% of those infected [29], which is consistent with the results of the serological analysis of the first wave [30]. If only half of those infected were symptomatic, although possibly with very mild symptoms (as this is typical for influenza), the CAR would be around 5–10%. If so, estimates of the CFR are around 0.01% [31,32], but higher levels have been reported in the literature: up to 0.05% in the US [31], 0.1% in Spain [33], and 0.35% in Europe [24], 0.6% in Mexico [34]. In terms of age groups, mortality was spread evenly across the age groups although most cases were reported in the younger age groups.

Definition of severity profiles and scenarios
Table 4, shows the severity profile for each of the four selected  parameters derived from the literature review and selected  by the suggestions of the panel of experts.

Table 4. Severity profile for the selected  parameters, study on pandemic influenza scenarios in Europe


 
With regard to CAR, the literature review reported data ranging from 0 to 50%. Nevertheless, since the maximum value of 50% refers to the extreme value reported during the 1889 ‘Russian’ pandemic [13,35-39], this value was excluded and, therefore, CAR maximum value was set at 35%.

Also for CFR, from the literature review the observed values ranged from 0% to 25% (Table 2). However, some of the data collected from the literature review were estimates of CFR derived from different populations (often representing high-risk groups) and source of information (mortality associated with the 2009 pandemic influenza A(H1N1) was estimated 15 times higher than reported laboratory-confirmed deaths) [40]. Moreover, when considering the influenza A(H5N1) avian influenza virus: CFR estimates reported by WHO for the ongoing outbreak is around 60% [41], even if, findings from a study based on surveillance and seroprevalence data published in 2008, reports estimates ranging from 14 to 33% [42]. For this reason we set the maximum level of the CFR at 2.5%, as most of values from recent pandemics ranged from 0.01 to 2.5% [13,14,32] (Table 3).

HAR depends on the level of virulence of the pandemic virus. However, its estimation may be affected by access to healthcare, proportion of chronic medical conditions in the population, pregnancy, and the virus characteristics (e.g. the level of pre-existing immunity, and pathogenicity of the virus itself). In our literature review we obtained values ranging from 0 to 27.5%. As the extreme value refer to pandemic 1918/19 in the US Army Camps¸ according to the opinions of the panel of experts set the maximum value to 4% as this value was collected in the general population [5].

For ICAR, it ranged from 0 to 35% in the literature review, and we considered the maximum of 35% as ‘reasonable worst case’ given that it was derived from an accurate evaluation of laboratory-confirmed influenza hospitalised cases conducted in the US [43].

Based on the above described ranges of values, it is possible to define 256 different scenarios. Among these, we selected  six reasonable scenarios, according to the opinion of the panel of experts (Figure 2).

Figure 2. Six possible scenarios identified by a combination of the selected  parameters, study on pandemic influenza scenarios in Europe


 
In detail, scenario A represents a ‘seasonal-like’ influenza outbreak; scenario B describes a situation in which the virus is quite diffusive, with an important HAR and a low virulence and ICAR, similar to the 2009 pandemic. The high HAR in scenario B could also represent high-risk groups (e.g. elderly, individuals with underlying conditions). Scenario C and D represent a situation in which the CAR is high with a low and a high virulence, respectively. Moreover, since the scenarios described above do not take into account the age profile of the population and the proportion of individuals with chronic conditions, we consider a reasonable solution to retain scenario E and F that represent the worst case scenarios for at-risk groups.

Discussion

In our study we defined a set of scenarios that may be useful for pandemic planning. We used the combination of four severity profiles of four epidemiological parameters to identify 256 possible scenarios that can be adapted over time and are far from the classic scenarios structure used for pandemic plans up to the 2009 influenza pandemic [1]. Among the scenarios identified, on the basis of a literature review and of the opinion of the panel of experts, we selected  the six most likely scenarios that synthesise the possible effect of an influenza outbreak with different characteristics (from a seasonal-like to a major event).

Historically, influenza pandemic planning has been based on an assessment of the ‘reasonable worst case’, derived from previous influenza seasons and pandemics in the 20th century, and thus has shown not to be appropriate during a moderate event, such as the 2009 pandemic [44]. Other experiences reported a modelling approach using a combination of indicators leading to a qualitative assessment in three levels (i.e. mild, moderate and severe) [5]; that approach was considered not to be specific enough to guide interventions [6]. Moreover, mathematical modelling based on preliminary epidemiological data is useful in defining the impact and the mitigation measures to be implemented during a pandemic. However, these models are strongly affected by the epidemiological parameters used and, even if they are able to explore a wide range of values, they need a specific set of scenarios to produce reliable results. For this reason, the use of scenarios in pandemic planning is crucial.

In our literature review, most of the selected  articles and documents were observational studies, mathematical simulations, or reviews. Information referring to different world regions, different population sub-groups and different influenza pandemics (mostly the 2009 influenza pandemic) over 100 years-period made comparison of results difficult. In fact, our results showed that most of the parameters values vary a lot between different countries and in different pandemics. For example, mortality rates often vary by age: age-specific mortality rates for 1957/58 and 1968/69 show a U-shaped pattern with a slightly increased CFR in the very young and an increasing one with older age [45]. On the other hand, during the 1918 pandemic, a higher mortality rate was observed in young adults followed by lower rates in other age groups [35]. Moreover, variation in epidemiological parameters could also reflect differences in the surveillance systems (e.g. in case of different case definitions, time lag between influenza confirmation and death, etc.) and diagnostic methods. This heterogeneous information presented in the documents did not allow us to use parts of the data (e.g. the absolute number of deaths was neglected where the corresponding denominator to calculate CFR was missing). It should also be noted that we did not consider age groups and the proportion of people with other underlying conditions that are strictly related to the vulnerability of the population to a pandemic virus [6]. Finally, estimates for the 2009/10 pandemic are likely to change as further data and studies become available after the literature review was conducted (December 2011).

The experience of the 2009 influenza pandemic showed that the EU countries had prepared for a pandemic of high severity but appeared unable to adapt their national and subnational responses adequately to a more moderate event. Knowledge of past pandemics is of substantial help when planning for a future one [46] and indeed the epidemiological aspects of the three 20th century influenza pandemics (1918/20, 1957/58, 1968/69) are of outstanding importance. However, modelling studies based on epidemiological parameters collected during the 20th century pandemics overestimated the impact of the 2009/10 pandemic [8]. Furthermore, society has undergone major changes since 1918 (the scenario on which most pandemic plans and models before and during the 2009 pandemic have been based) and even since 1968, with an increased availability of ICUs and clinical countermeasures (such as vaccines, antivirals, etc.).

Thus, in June 2013, the WHO published the ‘Pandemic Influenza Risk Management’ [8]. The approach taken in this document introduces a risk-based approach to pandemic influenza risk management and encourages countries to develop flexible plans, and to conduct risk assessments in order to prioritise the development of risk management programmes tailored to the hazards present. Our results are in line with the ‘WHO Pandemic Influenza Risk Management’ [8] and provide a description of possible scenarios of pandemic influenza considering key epidemiological parameters. The described scenarios allow severity assessments and provide the basis for developing flexible risk management plans over the course of a pandemic.

In the context of the FLURESP Project, the proposed scenarios have been used to select  potential response strategies (clustered and ranked according to performance and efficiency using a multi-criteria analysis) in order to conduct cost-effectiveness evaluations to compare cost and performance of response strategies for each proposed scenario.

Our study, although not based on a standardised procedure, is supported by an extensive literature review and suggestions derived from a panel of experts.

In conclusion, our study provides an original template to categorise human influenza pandemic scenarios, useful for pandemic planning. Before using its outcomes, limitations should be taken into account by public health authorities dealing with pandemic planning. This study is the first step of the FLURESP project, whose objective is to define adequate public health responses and measures according to each scenario presented in this paper and to compare performance and cost-effectiveness of such measures.


Acknowledgements
This work was possible thanks to research funding provided by the EU DG-Sanco for the FLURESP Project (Grant agreement no. 2010-11-01). We thank Dr Peter G Grove and Dr Guy Walker for their useful insights.

Conflicts of interest
None declared.

Authors’ contributions
The work presented here was carried out in collaboration between all authors. C.N. M.F. and C.R. contributed to the data collection, performed the analysis and drafted the manuscript. . C.N., M.F., C.R., A.Bo., S.Bo., M.B., J.O., J.M.C., L.N., P.G., A.P., C.L. and C.G. interpreted the results. S.Br., A.N. and P.P contributed to the methodological approach. A.Be. conceived the overall study aims and design. All authors have contributed to, seen and approved the manuscript.


References

  1. World Health Organization (WHO). WHO global influenza preparedness plan. Geneva: WHO. 2005. [Accessed April 2013]. Available from: http://www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_5.pdf
  2. World Health Organization. Epidemiology of WHO-confirmed human cases of avian influenza A(H5N1) infection. Wkly Epidemiol Rec. 2006;81(26):249-57. PMID:16812929
  3. World Health Organization (WHO). Pandemic Influenza A (H1N1). Geneva: WHO. 2011. [Accessed April 2013]. Available from: http://www.who.int/csr/resources/publications/swineflu/h1n1_donor_032011.pdf
  4. United Kingdom Department of Health. UK Influenza Pandemic Preparedness Strategy 2011. London: Department of Health. 10 Nov 2011. [Accessed April 2013]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/213717/dh_131040.pdf
  5. Ajelli M, Gonçalves B, Balcan D, Colizza V, Hu H, Ramasco JJ, et al. Comparing large-scale computational approaches to epidemic modeling: agent-based versus structured metapopulation models. BMC Infect Dis. 2010;10(1):190. http://dx.doi.org/10.1186/1471-2334-10-190 PMID:20587041
  6. World Health Organization. Considerations for assessing the severity of an influenza pandemic. Wkly Epidemiol Rec. 2009;84(22):197-202. Last accessedApril2013. Available from: http://www.who.int/wer/2009/wer8422/en/index.html PMID:19480086
  7. World Health Organization (WHO). Strengthening response to pandemics and other public-health emergencies. Geneva: WHO. 2011. [Accessed April 2013]. Available from: http://www.who.int/ihr/publications/RC_report/en/index.html
  8. World Health Organization (WHO). Pandemic Influenza Risk Management. WHO Interim Guidance. Geneva: WHO. 2013. [Accessed July 2014]. Available from: http://www.who.int/influenza/preparedness/pandemic/GIP_PandemicInfluenzaRiskManagementInterimGuidance_Jun2013.pdf?ua=1
  9. European Centre for Disease Control and Prevention (ECDC). ECDC health information. Pandemic (H1N1) 2009 planning assumptions to end of May 2010 for EU/EEA countries. Stockholm: ECDC. 11 Nov 2009. [Accessed April 2013]. Available from: http://www.ecdc.europa.eu/en/healthtopics/Documents/091111_Pandemic_(H1N1)_2009_Planning_Assumptions_for_EU_EEA_countries.pdf
  10. Yu H, Feng L, Peng Z, Feng Z, Shay DK, Yang W. Estimates of the impact of a future influenza pandemic in China. Influenza Other Respi Viruses. 2009;3(5):223-31. http://dx.doi.org/10.1111/j.1750-2659.2009.00093.x PMID:21462394
  11. Miller MA, Viboud C, Olson DR, Grais RF, Rabaa MA, Simonsen L. Prioritization of influenza pandemic vaccination to minimize years of life lost. J Infect Dis. 2008;198(3):305-11. http://dx.doi.org/10.1086/589716 PMID:18558871
  12. Department of Health. Scientific Pandemic Influenza Advisory Committee (SPI): Subgroup on Modelling. Modelling Summary. 13 Jun 2013. London: Department of Health. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/208264/SPI-M_Modelling_Summary_13_06_13.pdf
  13. Nguyen-Van-Tam JS, Hampson AW. The epidemiology and clinical impact of pandemic influenza. Vaccine. 2003;21(16):1762-8. http://dx.doi.org/10.1016/S0264-410X(03)00069-0 PMID:12686091
  14. World Health Organization (WHO). Pandemic influenza preparedness and response. Geneva: WHO. 2009. [Accessed April 2013]. Available from: http://whqlibdoc.who.int/publications/2009/9789241547680_eng.pdf
  15. Rizzo C, Bella A, Viboud C, Simonsen L, Miller MA, Rota MC, et al. Trends for influenza-related deaths during pandemic and epidemic seasons, Italy, 1969-2001. Emerg Infect Dis. 2007;13(5):694-9. http://dx.doi.org/10.3201/eid1305.061309 PMID:17553246
  16. Yang L, Chan KP, Cowling BJ, Chiu SS, Chan KH, Peiris JS, et al. Excess mortality associated with the 2009 pandemic of influenza A(H1N1) in Hong Kong. Epidemiol Infect. 2012;140(09):1542-50. http://dx.doi.org/10.1017/S0950268811002238 PMID:22074735
  17. O’Dowd A. Swine flu claims first European death, as cases worldwide rise to 36,000. BMJ. 2009;338(jun16 3):b2470. http://dx.doi.org/10.1136/bmj.b2470 PMID:19531555
  18. Nishiura H. Case fatality ratio of pandemic influenza. Lancet Infect Dis. 2010;10(7):443-4. http://dx.doi.org/10.1016/S1473-3099(10)70120-1 PMID:20610325
  19. Nishiura H. The virulence of pandemic influenza A (H1N1) 2009: an epidemiological perspective on the case-fatality ratio. Expert Rev Respir Med. 2010;4(3):329-38. http://dx.doi.org/10.1586/ers.10.24 PMID:20524916
  20. Duque V, Cordeiro E, Mota V, Vaz J, Morais C, Rodrigues F, et al. The early days of pandemic (H1N1) 2009 virus infection in the central region of Portugal. Rev Port Pneumol. 2010;16(6):870-9. PMID:21067692
  21. Chowell G, Echevarría-Zuno S, Viboud C, Simonsen L, Tamerius J, Miller MA, et al. Characterizing the epidemiology of the 2009 influenza A/H1N1 pandemic in Mexico. PLoS Med. 2011;8(5):e1000436. http://dx.doi.org/10.1371/journal.pmed.1000436 PMID:21629683
  22. Bandaranayake D, Huang QS, Bissielo A, Wood T, Mackereth G, Baker MG, et al. Risk factors and immunity in a nationally representative population following the 2009 influenza A(H1N1) pandemic. PLoS ONE. 2010;5(10):e13211. http://dx.doi.org/10.1371/journal.pone.0013211 PMID:20976224
  23. Hak E, Meijboom MJ, Buskens E. Modelling the health-economic impact of the next influenza pandemic in The Netherlands. Vaccine. 2006;24(44-46):6756-60. http://dx.doi.org/10.1016/j.vaccine.2006.05.065 PMID:16797797
  24. European Centre for Disease Control and Prevention (ECDC). Planning assumption for first wave of pandemic H1N1 2009 in Europe. Stockholm: ECDC. 29 Jul 2009. [Accessed April 2013]. Available from: http://www.ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?ID=88&List=a3216f4c-f040-4f51-9f77-a96046dbfd72
  25. Cui F, Luo H, Zhou L, Yin D, Zheng C, Wang D, et al. Transmission of pandemic influenza A (H1N1) virus in a train in China. J Epidemiol. 2011;21(4):271-7. http://dx.doi.org/10.2188/jea.JE20100119 PMID:21646746
  26. Huai Y, Lin J, Varma JK, Peng Z, He J, Cheng C, et al. A primary school outbreak of pandemic 2009 influenza A (H1N1) in China. Influenza Other Respi Viruses. 2010;4(5):259-66. http://dx.doi.org/10.1111/j.1750-2659.2010.00150.x PMID:20795308
  27. Centers for Disease Control and Prevention (CDC). Outbreak of 2009 pandemic influenza A (H1N1) on a Peruvian Navy ship - June-July 2009. MMWR Morb Mortal Wkly Rep. 2010;59(6):162-5. PMID:20168295
  28. Mahato RK, Bhandari GP, Shrestha JM, Basnet P. Pandemic influenza A (H1N1) 2009 outbreak investigation in Nepal. J Nepal Health Res Counc. 2010;8(2):75-7. PMID:21876566
  29. Baguelin M, Hoschler K, Stanford E, Waight P, Hardelid P, Andrews N, et al. Age-specific incidence of A/H1N1 2009 influenza infection in England from sequential antibody prevalence data using likelihood-based estimation. PLoS ONE. 2011;6(2):e17074. http://dx.doi.org/10.1371/journal.pone.0017074 PMID:21373639
  30. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet. 2010;375(9720):1100-8. http://dx.doi.org/10.1016/S0140-6736(09)62126-7 PMID:20096450
  31. Presanis AM, De Angelis D, Hagy A, Reed C, Riley S, Cooper BS, et al. The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis. PLoS Med. 2009;6(12):e1000207. http://dx.doi.org/10.1371/journal.pmed.1000207 PMID:19997612
  32. Presanis AM, Lipsitch M, De Angelis, Swine Flu Investigation Team, New York City Department of Health and Mental Hygiene, Hagy A, et al. The severity of pandemic H1N1 influenza in the United States, April - July 2009. PLoS Curr. 2009;1:RRN1042. PMID:20029614
  33. Santa-Olalla Peralta P, Cortes García M, Martínez Sánchez EV, Nogareda Moreno F, Limia Sánchez A, Pachón Del Amo I, et al. [Enhanced surveillance of initial cases of pandemic influenza (H1N1) 2009 infection in Spain, April-June 2009]. Rev Esp Salud Publica. 2010;84(5):529-46. [Spanish]. http://dx.doi.org/10.1590/S1135-57272010000500007 PMID:21203718
  34. World Health Organization (WHO). Public health measures during the influenza A(H1N1) 2009 pandemic 2011. Geneva: WHO. 2011. [Accessed April 2013]. Available from: http://whqlibdoc.who.int/hq/2011/WHO_HSE_GIP_ITP_2011.3_eng.pdf
  35. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med. 1987;82(6) 6A;20-5. http://dx.doi.org/10.1016/0002-9343(87)90556-0 PMID:3591814
  36. Mann PG, Pereira MS, Smith JW, Hart RJ, Williams WO, Dunhill B. A five-year study of influenza in families. Joint Public Health Laboratory Service/Royal College of General Practitioners working group. J Hyg (Lond). 1981;87(02):191-200. http://dx.doi.org/10.1017/S0022172400069400 PMID:7288174
  37. Longini IM Jr, Halloran ME, Nizam A, Yang Y. Containing pandemic influenza with antiviral agents. Am J Epidemiol. 2004;159(7):623-33. http://dx.doi.org/10.1093/aje/kwh092 PMID:15033640
  38. Fleming DM. The contribution of influenza to combined acute respiratory infections, hospital admissions, and deaths in winter. Commun Dis Public Health. 2000;3(1):32-8. PMID:10743316
  39. Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167(7):775-85. http://dx.doi.org/10.1093/aje/kwm375 PMID:18230677
  40. Dawood FS, Iuliano AD, Reed C, Meltzer MI, Shay DK, Cheng PY, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis. 2012;12(9):687-95. http://dx.doi.org/10.1016/S1473-3099(12)70121-4 PMID:22738893
  41. World Health Organization (WHO). Influenza at the Human-Animal Interface. Geneva: WHO. [Accessed April 2013]. Available from: www.who.int/csr/disease/avian_influenza/
  42. Li FC, Choi BC, Sly T, Pak AW. Finding the real case-fatality rate of H5N1 avian influenza. J Epidemiol Community Health. 2008;62(6):555-9. http://dx.doi.org/10.1136/jech.2007.064030 PMID:18477756
  43. Skarbinski J, Jain S, Bramley A, Lee EJ, Huang J, Kirschke D, et al. Hospitalized patients with 2009 pandemic influenza A (H1N1) virus infection in the United States--September-October 2009. Clin Infect Dis. 2011;52(1) Suppl 1;S50-9. http://dx.doi.org/10.1093/cid/ciq021 PMID:21342900
  44. Reed C, Biggerstaff M, Finelli L, Koonin LM, Beauvais D, Uzicanin A, et al. Novel framework for assessing epidemiologic effects of influenza epidemics and pandemics. Emerg Infect Dis. 2013;19(1):85-91. http://dx.doi.org/10.3201/eid1901.120124 PMID:23260039
  45. Simonsen L, Clarke MJ, Schonberger LB, Arden NH, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis. 1998;178(1):53-60. http://dx.doi.org/10.1086/515616 PMID:9652423
  46. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics--implications for policy. N Engl J Med. 2009;360(25):2595-8. http://dx.doi.org/10.1056/NEJMp0903906 PMID:19423872
  47. Balcan D, Hu H, Goncalves B, Bajardi P, Poletto C, Ramasco JJ, et al. Seasonal transmission potential and activity peaks of the new influenza A(H1N1). A Monte Carlo likelihood analysis based on human mobility. BMC Med. 2009;10:7:45. doi: 10.1186/1741-7015-7-45.
  48. Chowell G, Ammon CE, Hengartner NW, Hyman JM. Estimation of the reproductive number of the Spanish flu epidemic in Geneva, Switzerland. Vaccine. 2006;24(44-46):6747-50. http://dx.doi.org/10.1016/j.vaccine.2006.05.055 PMID:16782243
  49. Chowell G, Nishiura H, Bettencourt LM. Comparative estimation of the reproduction number for pandemic influenza from daily case notification data. J R Soc Interface. 2007;4(12):155-66. http://dx.doi.org/10.1098/rsif.2006.0161 PMID:17254982
  50. Chowell G, Viboud C, Munayco CV, Gómez J, Simonsen L, Miller MA, et al. Spatial and temporal characteristics of the 2009 A/H1N1 influenza pandemic in Peru. PLoS ONE. 2011;6(6):e21287. http://dx.doi.org/10.1371/journal.pone.0021287 PMID:21712984
  51. Colizza V, Barrat A, Barthelemy M, Valleron AJ, Vespignani A. Modeling the worldwide spread of pandemic influenza: baseline case and containment interventions. PLoS Med. 2007;4(1):e13. http://dx.doi.org/10.1371/journal.pmed.0040013 PMID:17253899
  52. Marchbanks TL, Bhattarai A, Fagan RP, Ostroff S, Sodha SV, Moll ME, et al.; Pennsylvania Working Group. An outbreak of 2009 pandemic influenza A (H1N1) virus infection in an elementary school in Pennsylvania. Clin Infect Dis. 2011;52(1) Suppl 1;S154-60. http://dx.doi.org/10.1093/cid/ciq058 PMID:21342888
  53. Novel influenza A(H1N1) investigation team. Description of the early stage of pandemic (H1N1) 2009 in Germany, 27 April-16 June 2009. Euro Surveill. 2009;14(31):19295. PMID:19660249
  54. Pandemic Flu Response Review Team. Cabinet Office (UK). The 2009 Influenza Pandemic: an independent official review of the UK response to the 2009 influenza pandemic. London: Cabinet Office. July 2010. [Accessed April 2013]. Available from: https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/61252/the2009influenzapandemic-review.pdf
  55. Polish Ministry of Health. Krajowy plan działań dla polski na wypadek wystąpienia kolejnej pandemii grypy [Polish National Action Plan in the event of the next influenza pandemic]. 10 Aug 2005. [Accessed April 2013]. Available from: http://www2.mz.gov.pl/wwwfiles/ma_struktura/docs/zalacznik_r_26.pdf,
  56. Simón Méndez L, de Mateo Ontañón S, Larrauri Cámara A, Jiménez-Jorge S, Vaqué Rafart J, Pérez Hoyos S; en representación del Sistema de Vigilancia de Gripe en España (SVGE). [Transmissibility and severity of the pandemic influenza A (H1N1) 2009 virus in Spain]. Gac Sanit. 2011;25(4):296-302. [Spanish] PMID:21543138
  57. Valleron AJ, Cori A, Valtat S, Meurisse S, Carrat F, Boëlle PY. Transmissibility and geographic spread of the 1889 influenza pandemic. Proc Natl Acad Sci USA. 2010;107(19):8778-81. http://dx.doi.org/10.1073/pnas.1000886107 PMID:20421481
  58. Viboud C, Tam T, Fleming D, Handel A, Miller MA, Simonsen L. Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. Vaccine. 2006;24(44-46):6701-7. http://dx.doi.org/10.1016/j.vaccine.2006.05.067 PMID:16806596
  59. World Health Organization (WHO). WHO checklist for influenza pandemic preparedness planning. Geneva: WHO. 2005. [Accessed April 2013]. Available from: http://whqlibdoc.who.int/hq/2005/WHO_CDS_CSR_GIP_2005.4.pdf
  60. World Health Organization (WHO). Pandemic influenza preparedness Framework 2011. Geneva: WHO. 2011. [Accessed April 2013]. Available from: http://whqlibdoc.who.int/publications/2011/9789241503082_eng.pdf
  61. Turkish Ministry of Health. Directorate General of Primary Health Care. Pandemic Influenza National Action Plan. Ankara: Ministry of Health. 2005.
  62. Franco-Paredes C, Hernandez-Ramos I, Del Rio C, Alexander KT, Tapia-Conyer R, Santos-Preciado JI. H1N1 influenza pandemics: comparing the events of 2009 in Mexico with those of 1976 and 1918-1919. Arch Med Res. 2009;40(8):669-72. http://dx.doi.org/10.1016/j.arcmed.2009.10.004 PMID:20304254
  63. Malta Health Division. Influenza Pandemic Contingency Plan for the Maltese Islands. Malta. 2007.
  64. Lee VJ, Chen MI. Effectiveness of neuraminidase inhibitors for preventing staff absenteeism during pandemic influenza. Emerg Infect Dis. 2007;13(3):449-57. http://dx.doi.org/10.3201/eid1303.060309 PMID:17552099
  65. Lessler J, Cummings DA, Fishman S, Vora A, Burke DS. Transmissibility of swine flu at Fort Dix, 1976. J R Soc Interface. 2007;4(15):755-62. http://dx.doi.org/10.1098/rsif.2007.0228 PMID:17412677
  66. Lessler J, Reich NG, Cummings DA, New York City Department of Health and Mental Hygiene Swine Influenza Investigation Team. Outbreak of 2009 pandemic influenza A (H1N1) at a New York City school. N Engl J Med. 2009;361(27):2628-36. http://dx.doi.org/10.1056/NEJMoa0906089 PMID:20042754
  67. Mills CE, Robins JM, Lipsitch M. Transmissibility of 1918 pandemic influenza. Nature. 2004;432(7019):904-6. http://dx.doi.org/10.1038/nature03063 PMID:15602562
  68. Jackson C, Vynnycky E, Mangtani P. Estimates of the transmissibility of the 1968 (Hong Kong) influenza pandemic: evidence of increased transmissibility between successive waves. Am J Epidemiol. 2010;171(4):465-78. http://dx.doi.org/10.1093/aje/kwp394 PMID:20007674
  69. Carrat F, Luong J, Lao H, Sallé AV, Lajaunie C, Wackernagel H. A 'small-world-like' model for comparing interventions aimed at preventing and controlling influenza pandemics. BMC Med. 2006;23:4:26.
  70. Correia AM, Queirós L, Dias J. Pandemic influenza A (H1N1) in the North of Portugal: how did the autumn-winter wave behave? Rev Port Pneumol. 2010;16(6):880-6. PMID:21067693
  71. United Kingdom Department of Health. Cabinet Office. Swine Flu. UK Planning Assumptions. London: Department of Health. 3 Sep 2009. [Accessed April 2013]. Avalaible from: http://webarchive.nationalarchives.gov.uk/20130107105354/http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_104843.pdf
  72. Doyle TJ, Hopkins RS; Transmission Investigation Team. Low secondary transmission of 2009 pandemic influenza A (H1N1) in households following an outbreak at a summer camp: relationship to timing of exposure. Epidemiol Infect. 2011;139(01):45-51. http://dx.doi.org/10.1017/S095026881000141X PMID:20561391
  73. Gomez J, Munayco C, Arrasco J, Suarez L, Laguna-Torres V, Aguilar P, et al. Pandemic influenza in a southern hemisphere setting: the experience in Peru from May to September, 2009. Euro Surveill. 2009;14(42):19371. PMID:19883547
  74. Gordon A, Saborío S, Videa E, López R, Kuan G, Balmaseda A, et al. Clinical attack rate and presentation of pandemic H1N1 influenza versus seasonal influenza A and B in a pediatric cohort in Nicaragua. Clin Infect Dis. 2010;50(11):1462-7. http://dx.doi.org/10.1086/652647 PMID:20420502
  75. Iuliano AD, Reed C, Guh A, Desai M, Dee DL, Kutty P, et al. Notes from the field: outbreak of 2009 pandemic influenza A (H1N1) virus at a large public university in Delaware, April-May 2009. Clin Infect Dis. 2009;49(12):1811-20. http://dx.doi.org/10.1086/649555 PMID:19911964
  76. Jhung MA, Swerdlow D, Olsen SJ, Jernigan D, Biggerstaff M, Kamimoto L, et al. Epidemiology of 2009 pandemic influenza A (H1N1) in the United States. Clin Infect Dis. 2011;52(1) Suppl 1;S13-26. http://dx.doi.org/10.1093/cid/ciq008 PMID:21342884
  77. Lee BY, Bailey RR, Wiringa AE, Assi TM, Beigi RH. Antiviral medications for pregnant women for pandemic and seasonal influenza: an economic computer model. Obstet Gynecol. 2009;114(5):971-80. http://dx.doi.org/10.1097/AOG.0b013e3181bdbfed PMID:20168096
  78. Leung YH, Li MP, Chuang SK. A school outbreak of pandemic (H1N1) 2009 infection: assessment of secondary household transmission and the protective role of oseltamivir. Epidemiol Infect. 2011;139(01):41-4. http://dx.doi.org/10.1017/S0950268810001445 PMID:20561390
  79. Li T, Liu Y, Di B, Wang M, Shen J, Zhang Y, et al. Epidemiological investigation of an outbreak of pandemic influenza A (H1N1) 2009 in a boarding school: serological analysis of 1570 cases. J Clin Virol. 2011;50(3):235-9. http://dx.doi.org/10.1016/j.jcv.2010.11.012 PMID:21195022
  80. Mayoral Cortés JM, Ruiz Fernández J, Pachón Díaz J, Navarro Marí JM, Puell Gómez L, Pérez Morilla E, et al. [Infection by the pandemic virus (H1N1) 2009 in Andalusia]. Rev Esp Salud Publica. 2010;84(5):517-28. http://dx.doi.org/10.1590/S1135-57272010000500006 PMID:21203717
  81. Nougairède A, Ninove L, Zandotti C, Salez N, Mantey K, Resseguier N, et al. Novel virus influenza A (H1N1sw) in South-Eastern France, April-August 2009. PLoS ONE. 2010;5(2):e9214. http://dx.doi.org/10.1371/journal.pone.0009214 PMID:20174643
  82. Office General delà santé Publique, Confederation Suisse: Plan suisse de pandémie Influenza. available at: http://www.bag.admin.ch/influenza/01120/01134/03058/index.html?lang=fr, Last accessed April 2013.
  83. Smith RD, Keogh-Brown MR, Barnett T. Estimating the economic impact of pandemic influenza: An application of the computable general equilibrium model to the U.K. Soc Sci Med. 2011;73(2):235-44. http://dx.doi.org/10.1016/j.socscimed.2011.05.025 PMID:21708419
  84. van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in the Netherlands: scenario analysis. Emerg Infect Dis. 2003;9(5):531-8. http://dx.doi.org/10.3201/eid0905.020321 PMID:12737735
  85. Wielders CC, van Lier EA, van ’t Klooster TM, van Gageldonk-Lafeber AB, van den Wijngaard CC, Haagsma JA, et al. The burden of 2009 pandemic influenza A(H1N1) in the Netherlands. Eur J Public Health. 2012;22(1):150-7. http://dx.doi.org/10.1093/eurpub/ckq187 PMID:21183472
  86. Wilson N, Mansoor O, Baker M. Estimating the impact of the next influenza pandemic on population health and health sector capacity in New Zealand. N Z Med J. 2004;118(1211):U1346.
  87. Yates L, Pierce M, Stephens S, Mill AC, Spark P, Kurinczuk JJ, et al. Influenza A/H1N1v in pregnancy: an investigation of the characteristics and management of affected women and the relationship to pregnancy outcomes for mother and infant. Health Technol Assess. 2010;14(34):109-82. http://dx.doi.org/10.3310/hta14340-02 PMID:20630123
  88. Barry JM, Viboud C, Simonsen L. Cross-protection between successive waves of the 1918-1919 influenza pandemic: epidemiological evidence from US Army camps and from Britain. J Infect Dis. 2008;198(10):1427-34. http://dx.doi.org/10.1086/592454 PMID:18808337
  89. Centers for Disease Control and Prevention (CDC). Outbreak of 2009 pandemic influenza A (H1N1) at a school - Hawaii, May 2009. MMWR Morb Mortal Wkly Rep. 2010;58(51):1440-4. PMID:20057351
  90. Cherifi S, Reynders M, Theunissen C. Hospital preparedness and clinical description of the 2009 influenza A (H1N1) pandemic in a Belgian tertiary hospital. J Hosp Infect. 2011;77(2):118-22. http://dx.doi.org/10.1016/j.jhin.2010.09.032 PMID:21216036
  91. Di Giambenedetto S, Zileri Dal Verme L, Sali M, Farina S, Di Cristo V, Manzara S, et al. Clinical presentation, microbiological features and correlates of disease severity of 2009 pandemic influenza A (H1N1) infection. Eur J Clin Microbiol Infect Dis. 2011;30(4):541-9. http://dx.doi.org/10.1007/s10096-010-1116-7 PMID:21104285
  92. Donaldson LJ, Rutter PD, Ellis BM, Greaves FE, Mytton OT, Pebody RG, et al. Mortality from pandemic A/H1N1 2009 influenza in England: public health surveillance study. BMJ. 2009;339(dec10 1):b5213. http://dx.doi.org/10.1136/bmj.b5213 PMID:20007665
  93. Fujikura Y, Kawana A, Kato Y, Mizuno Y, Kudo K. [Clinical features in fatal Spanish influenza: Japanese Army Hospital medical records investigation]. Kansenshogaku Zasshi. 2010;84(2):165-70. [Japanese]. PMID:20420160
  94. Jain S, Kamimoto L, Bramley AM Schmitz AM, Benoit SR, Louie J, et al. Hospitalized Patients with 2009 H1N1 Influenza in the United States, April–June 2009. N Engl J Med. 2009; 361(20):1935-44. doi: 10.1056/NEJMoa0906695.
  95. Louie JK, Acosta M, Winter K, Jean C, Gavali S, Schechter R, et al.California Pandemic (H1N1) Working Group. Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA. 2009;302(17):1896-902. http://dx.doi.org/10.1001/jama.2009.1583 PMID:19887665
  96. Al Hajjar S, McIntosh K; Sami Al Hajjara and Kenneth McIntoshb. The first influenza pandemic of the 21st century. Ann Saudi Med. 2010;30(1):1-10. PMID:20103951
  97. Santa-Olalla Peralta P, Cortes-García M, Vicente-Herrero M, Castrillo-Villamandos C, Arias-Bohigas P, Pachon-del Amo I, et al. Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April - December 2009. Euro Surveill. 2010;15(38):19667. PMID:20929651
  98. Shieh WJ, Blau DM, Denison AM, Deleon-Carnes M, Adem P, Bhatnagar J, et al. 2009 pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States. Am J Pathol. 2010;177(1):166-75. http://dx.doi.org/10.2353/ajpath.2010.100115 PMID:20508031
  99. Han K, Zhu XP, He F, Liu LG, Zhang LJ, Ma HL, et al. [Non-airborne transmission during outbreak of pandemic (H1N1) 2009 among tour group members, China, June 2009]. Zhonghua Liu Xing Bing Xue Za Zhi. 2010;31(9):1046-9. [Chinese]. PMID:21162874
  100. Koopmans M, Wilbrink B, Conyn M, Natrop G, van der Nat H, Vennema H, et al. Transmission of H7N7 avian influenza A virus to human beings during a large outbreak in commercial poultry farms in the Netherlands. Lancet. 2004;363(9409):587-93. http://dx.doi.org/10.1016/S0140-6736(04)15589-X PMID:14987882
  101. Cao B, Li XW, Mao Y, Wang J, Lu HZ, Chen YS, et al. Clinical features of the initial cases of 2009 pandemic influenza A (H1N1) virus infection in China. N Engl J Med. 2009;361(26):2507-17. http://dx.doi.org/10.1056/NEJMoa0906612 PMID:20007555
  102. Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9(5):291-300. http://dx.doi.org/10.1016/S1473-3099(09)70069-6 PMID:19393959
  103. Yang TH, Chu D, Hu BS, Hung YT, Chou P. Early experience of the pandemic influenza H1N1 2009 epidemic in Taiwan. J Chin Med Assoc. 2011;74(7):298-304. http://dx.doi.org/10.1016/j.jcma.2011.05.005 PMID:21783094
  104. Yuan J, Zhang L, Xu W, Shen J, Zhang P, Ma H. Reported changes in health-related behaviours in Chinese urban residents in response to an influenza pandemic. Epidemiol Infect. 2009;137(07):988-93. http://dx.doi.org/10.1017/S0950268809002726 PMID:19426571
  105. AlMazroa MA, Memish ZA, AlWadey AM. Pandemic influenza A (H1N1) in Saudi Arabia: description of the first one hundred cases. Ann Saudi Med. 2010;30(1):11-4. PMID:20103952
  106. Balter S, Gupta LS, Lim S, Fu J, Perlman SE. Pandemic (H1N1) 2009 surveillance for severe illness and response, New York, USA, April-July 2009. Emerg Infect Dis. 2010;16(8):1259-64. http://dx.doi.org/10.3201/eid1608.091847 PMID:20678320
  107. van Genugten ML, Heijnen ML. The expected number of hospitalisations and beds needed due to pandemic influenza on a regional level in the Netherlands. Virus Res. 2004;103(1-2):17-23. http://dx.doi.org/10.1016/j.virusres.2004.02.007 PMID:15163483
  108. Martinese F, Keijzers G, Grant S, Lind J. How would Australian hospital staff react to an avian influenza admission, or an influenza pandemic? Emerg Med Australas. 2009;21(1):12-24. http://dx.doi.org/10.1111/j.1742-6723.2008.01143.x PMID:19254308
  109. Ercole A, Taylor BL, Rhodes A, Menon DK. Modelling the impact of an influenza A/H1N1 pandemic on critical care demand from early pathogenicity data: the case for sentinel reporting. Anaesthesia. 2009;64(9):937-41. http://dx.doi.org/10.1111/j.1365-2044.2009.06070.x PMID:19645759


Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.
 

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.